Responses
Scientific Abstracts
Paediatric rheumatology
SAT0485 Safety Profile of the IL-1 Receptor Antagonist Kineret® (Anakinra) in a Long-Term Outcome Study in Patients with Severe Cryopyrin-Associated Periodic Syndromes (Caps)
Compose a Response to This Article
Other responses
No responses have been published for this article.